A Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE)

NCT05468632 · Completed

Last updated 2026-05-28

This study looks back at medical records in North Macedonia to examine how a diabetes medication called GLP-1 affects people with type 2 diabetes in real-world settings.

Status Completed The study has finished.

Type Observational

Participants 314 people

Who can join Ages 18+ · all sexes

Timeline Started 2022-07 · est. completion 2022-07

Where 17 sites · North Macedonia

What this study is testing ClinicalTrials.gov NCT05468632 ↗

Description as written by the study sponsor.

The purpose of this study is to investigate glycaemic control and other clinical parameters in glucagon like peptide -1 (GLP-1) naive adult participants with type 2 diabetes (T2D) who initiated once weekly (OW) semaglutide in local clinical practice in North Macedonia. The participants were treated according to current clinical practice, applicable local labels, and standard of care as per physicians' discretion. The total duration of the study is planned to be approximately 30 weeks which is the period from OW semaglutide initiation to end of follow up.

Treatments tested

Semaglutide Drug

Participants who initiated once weekly (OW) semaglutide in routine clinical practice in were enrolled in the study. The participants were treated according to current clinical practice, applicable local labels, and standard of care as per physicians' discretion.

Main thing measured	Change in glycated haemoglobin (HbA1c)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05468632 ↗